Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen
- Generic Name
- Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen
- Brand Names
- Trumenba
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 583WCD0IZI
Overview
Neisseria meningitidis serogroup B recombinant lp2086 a05 protein variant antigen is a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily A and one from subfamily B (A05 and B01, respectively).
Background
Neisseria meningitidis serogroup B recombinant lp2086 a05 protein variant antigen is a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily A and one from subfamily B (A05 and B01, respectively).
Indication
No indication information available.
Associated Conditions
- Infection caused by Neisseria Meningitidis Serogroup B
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.